Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 16/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29808738 | 0.88 | ELANE (0.58) | ELANE | |
| SCHEMBL4022883 | 0.88 | ELANE (0.58) | ELANE | |
| SCHEMBL4157841 | 0.87 | ELANE (0.57) | ELANE | |
| SCHEMBL4021428 | 0.87 | ELANE (0.57) | ELANE | |
| SCHEMBL31028425 | 0.87 | ELANE (0.57) | ELANE | |
| SCHEMBL4023525 | 0.86 | ELANE (0.57) | ELANE | |
| SCHEMBL4023914 | 0.86 | ELANE (0.56) | ELANE | |
| SCHEMBL4027419 | 0.86 | ELANE (0.56) | ELANE | |
| SCHEMBL4022876 | 0.81 | ELANE (0.63) | ELANE | |
| SCHEMBL4021644 | 0.81 | ELANE (0.63) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131483-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | HANSEN PETER | 2009-05-21 | — | — | US | claimed |
| EP-1861370-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | AstraZeneca AB (SE) | 2007-12-05 | — | — | EP | claimed |
| WO-2006098683-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-09-21 | — | — | WO | claimed |
| US-20090131483-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | HANSEN PETER | 2009-05-21 | — | — | US | disclosed |
| EP-1861370-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | AstraZeneca AB (SE) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006098683-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131483-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | SERPINB1, ELANE, MPO | ELANE 2/4885RXFP1 985/4885HTR2A 4211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.